downward shift guidanc expect
higher end new rang look achiev
strong quarter guidanc reduc result reflect anoth strong quarter
complement franchis growth primarili driven nmosd/gmg strensiq management
reduc guidanc note covid impact new start potenti shift payor
mix alxn commerci product address high-unmet need indic expect
lower covid impact rel coverag univers assum pt visit normal mid-
think may still achiev initi plan upper end new guidanc rang
modest impact clinic timelin expect compani suggest
potenti impact trial on-going enrollment/sit activ life-cycl
manag initi ultomiri track high-concentr iv review sc
data importantli ultomiri gmg/nmosd trial underway
al trial began dose march though increment site activ like slow
progress neuro indic crucial expand complement franchis commerci
opportun al high valu option pipelin also note stop
ultomiri ppm develop near-term expect data danicopan
may open door broader opportun renal indic
investor feedback acquisit management expect transact
diversifi commerci product line leverag global commerci infrastructur
relationship hospit channel investor pushback deal focus opportun
cost critic cite portola anoth deal fall short provid transform
potenti term commerci pipelin mix frustrat investor
alxn bd conservat continu credit compani adher vision
achiev improv diversif sustain time note current guidanc
exclud impact portola acquisit
model updat tp adjust updat model actual
adjust revenue/expens project reflect guidance/expect impact covid
adjust tp non-gaap ep vs prior
risk includ clinic regulatori commerci headwind competitor updat
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
alexion biotechnolog compani focus research develop
commerci therapeut rare diseas alexion drug soliri
use treat patient complement mediat disord
product includ strensiq kanuma
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
abl convert major soliri patient prior
launch biosimilar continu strength gmg nmo
launch increas valu al fcrn option
unabl convert major soliri patient prior
launch biosimilar eu/row weak gmg/nmosd
trend decreas pipelin valu
 close
figur guidanc lower owe weak new pt start
guidanc guidanc mcomplement mmetabol mr total total per million except ep actualcon qoq yoy incom tax incom incom dil charl martineau univers toronto may
compani mention price
martin auster tiago fauth certifi respect compani secur individu analyz view
express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
